首页> 美国卫生研究院文献>BMC Complementary and Alternative Medicine >In vitro synergism of magnolol and honokiol in combination with antibacterial agents against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA)
【2h】

In vitro synergism of magnolol and honokiol in combination with antibacterial agents against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA)

机译:厚朴酚和厚朴酚与抗菌药物联合对付耐甲氧西林金黄色葡萄球菌(MRSA)临床分离株的体外协同作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundMethicillin-resistant Staphylococcus aureus (MRSA) is a problematic pathogen posing a serious therapeutic challenge in the clinic. It is often multidrug-resistant (MDR) to conventional classes of antibacterial agents and there is an urgent need to develop new agents or strategies for treatment. Magnolol (ML) and honokiol (HL) are two naturally occurring diallylbiphenols which have been reported to show inhibition of MRSA. In this study their synergistic effects with antibacterial agents were further evaluated via checkerboard and time-kill assays.
机译:背景耐甲氧西林金黄色葡萄球菌(MRSA)是一个有问题的病原体,在临床上构成了严重的治疗挑战。它通常对常规类别的抗菌剂具有多重耐药性(MDR),因此迫切需要开发新的抗菌剂或治疗策略。厚朴酚(ML)和厚朴酚(HL)是两种天然存在的二烯丙基双酚,据报道对MRSA具有抑制作用。在这项研究中,通过棋盘和时间杀灭试验进一步评估了它们与抗菌剂的协同作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号